BIOTECH ASSISTANT / FIELD NOTES

Enlicitide reports address durability and baseline cardiovascular risk

Industry reporting · AJMC

Source published: 2026-11-02

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.

Why it may matter

Durability matters for chronic oral therapy, but selected extension populations and unproven cardiovascular outcomes remain important limits when interpreting commercial potential.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oral cyclic peptides

Related updates

2026-10-30Aurinia / SEC

Aurinia reports $232.4 million in nine-month LUPKYNIS net product sales

Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.

Oral cyclic peptides Ask AI ↗

2026-10-29Acta Pharmaceutica Sinica B

New review maps evidence standards for orally active peptides

A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.

Oral cyclic peptides Ask AI ↗

2026-10-29npj Drug Discovery

Review sets a higher bar for generative AI in constrained peptides

An npj Drug Discovery review examines how generative models represent constrained peptide chemistry, topology, conformational ensembles, and developability. It separates information explicitly generated by a model from properties inferred later, and predictions from prospective experiments. The authors identify gaps in chemical coverage and uncertainty calibration, including limitations relevant to orally absorbed cyclic peptides.

Oral cyclic peptides Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗